Home » Topics » BioWorld Science

BioWorld Science
RSS

Recommended phase II dose established in first-in-human study of 2X-121

June 13, 2018

FDA awards fast track designation to RGX-111 for MPS I

June 13, 2018

Japanese authorities grant priority review to lorlatinib application

June 13, 2018

ProQR Therapeutics enters partnership to advance development of QR-313

June 13, 2018

Senhwa Biosciences and PBTC to study CX-4945 in pediatric recurrent medulloblastoma

June 13, 2018

Herantis initiates phase II study of Lymfactin for secondary lymphedema

June 13, 2018

Galmed reports 1-year data from phase IIb study of Aramchol in NASH

June 13, 2018

E-Scape Bio obtains rights to S1P5 receptor agonists from AbbVie for lysosomal storage disorders

June 13, 2018

FDA approves Keytruda for recurrent or metastatic cervical cancer whose tumors express PD-L1

June 13, 2018

IMPACT Therapeutics identifies WEE1hu inhibitors

June 13, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...